Forbion discloses 7.1% MapLight Therapeutics (MPLT) ownership stake

Rhea-AI Filing Summary

Forbion Growth Opportunities Fund III Cooperatief U.A. and Forbion Growth III Management B.V. report a 7.1% beneficial ownership stake in MapLight Therapeutics, Inc. voting common stock. They beneficially own 3,226,400 shares with shared voting and dispositive power and no sole power over any shares. This percentage is based on 45,373,033 MapLight common shares outstanding as of November 24, 2025, as cited from the company’s Form 10-Q. Both reporting entities are organized in the Netherlands and file jointly on this Schedule 13G.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

MapLight Therapeutics, Inc.

(Name of Issuer)

Voting Common Stock, par value $0.0001 per share

(Title of Class of Securities)

56565P103

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 56565P103

1

Names of Reporting Persons

Forbion Growth Opportunities Fund III Cooperatief U.A.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,226,400.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,226,400.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,226,400.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 56565P103

1

Names of Reporting Persons

Forbion Growth III Management B.V.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NETHERLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,226,400.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,226,400.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,226,400.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MapLight Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 800 CHESAPEAKE DRIVE, REDWOOD CITY, CA 94063
Item 2.
(a)	Name of person filing: This statement is being filed by Forbion Growth Opportunities Fund III Cooperatief U.A. ("Forbion Growth III COOP") and Forbion Growth III Management B.V. ("Forbion Growth III"). Forbion Growth III COOP and Forbion Growth III are sometimes referred to collectively as the "Reporting Persons".
(b)	Address or principal business office or, if none, residence: The address of the principal business and principal office of each of the Reporting Persons is c/o Forbion Capital Partners, Gooimeer 2-35, 1411 DC Naarden, The Netherlands.
(c)	Citizenship: Each of the Reporting Persons is organized under the laws of the Netherlands.
(d)	Title of class of securities: Voting Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 56565P103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Forbion Growth III COOP directly owns 3,226,400 shares of Common Stock of the Issuer. Forbion Growth III, as the director of Forbion Growth III COOP, may be deemed to have voting and investment power over the shares held directly by Forbion Growth III COOP.
(b)	Percent of class: The shares of Common Stock beneficially owned by the Reporting Persons represent approximately 7.1% of the outstanding Common Stock, based upon 45,373,033 shares of Common Stock outstanding as of November 24, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on December 4, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,226,400
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,226,400
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Forbion Growth Opportunities Fund III Cooperatief U.A.

Signature:	/s/ G.J Mulder and /s/ M.A. van Osch
Name/Title:	Directors of its Director
Date:	02/17/2026

Forbion Growth III Management B.V.

Signature:	/s/ G.J Mulder and /s/ M.A. van Osch
Name/Title:	Directors
Date:	02/17/2026

FAQ

How many MapLight Therapeutics (MPLT) shares does Forbion report owning?

Forbion reports beneficial ownership of 3,226,400 MapLight common shares. This stake is held with shared voting and dispositive power and no sole power over any shares, according to the Schedule 13G ownership disclosure.

What percentage of MapLight Therapeutics (MPLT) does Forbion’s stake represent?

Forbion’s reported position represents 7.1% of MapLight’s outstanding common stock. This percentage is calculated using 45,373,033 shares outstanding as of November 24, 2025, as referenced from MapLight’s Form 10-Q.

Which entities are the reporting persons in the MapLight (MPLT) Schedule 13G?

The reporting persons are Forbion Growth Opportunities Fund III Cooperatief U.A. and Forbion Growth III Management B.V.. Forbion Growth III Management B.V., as director of the fund, may be deemed to have voting and investment power over the fund’s MapLight shares.

Does Forbion have sole or shared voting power over MapLight (MPLT) shares?

Forbion reports 0 shares with sole voting power and 3,226,400 shares with shared voting power. The same figures apply to dispositive power, indicating all reported MapLight shares are controlled on a shared basis.

On what share count is Forbion’s 7.1% MapLight (MPLT) ownership based?

The 7.1% ownership figure is based on 45,373,033 MapLight common shares outstanding. This outstanding share count is stated as of November 24, 2025, and is taken from MapLight’s Quarterly Report on Form 10-Q.

Where are the Forbion reporting entities in the MapLight (MPLT) filing organized and located?

Both Forbion reporting entities are organized under the laws of the Netherlands. Their principal business and office address is listed as c/o Forbion Capital Partners, Gooimeer 2-35, 1411 DC Naarden, The Netherlands in the Schedule 13G.